Logo 1.png
Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones
January 17, 2023 08:05 ET | Aeterna Zentaris Inc
Aeterna Zentaris focused on accelerating recruitment for ongoing DETECT trial and efforts to partner rights to Macrilen™ in the U.S. and CanadaCompany continues to build growing body of data across...
Logo 1.png
Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference
January 05, 2022 08:36 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Logo 1.png
Aeterna Zentaris Reports Third Quarter 2021 Financial Results and Provides Pipeline Program Updates
November 04, 2021 16:05 ET | Aeterna Zentaris Inc
– Company continues to build strong developmental pipeline – Supported by solid cash position TORONTO, ONTARIO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS)...
Logo 1.png
Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics
January 28, 2021 08:05 ET | Aeterna Zentaris Inc
- Company licenses exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific immunosuppressive therapeutic proteins for the potential treatment of neuromyelitis...